Skip to main content

Table 4 Associations between TLI status and OS or DFS rates of the patient subgroups

From: Is the thymidine labeling index a good prognostic marker in breast cancer?

 

5-year DFS rate (%)

P-value

5-year OS rate (%)

P-value

Patients with adjuvant chemotherapy (n = 205)

 

0.272

 

0.224

   Low TLI

75

 

89

 

   High TLI

68

 

80

 

Patients without adjuvant chemotherapy (n = 63)

 

0.663

 

0.634

   Low TLI

83

 

95

 

   High TLI

89

 

96

 

Patients with adjuvant hormonal therapy(n = 187)

 

0.512

 

0.824

   Low TLI

79

 

89

 

   High TLI

78

 

89

 

Patients without adjuvant hormonal therapy (n = 81)

 

0.933

 

0.164

   Low TLI

69.4

 

88.9

 

   High TLI

63.5

 

74.4

 

Patients with stage I (n = 54)

 

0.474

 

0.05

   Low TLI

88.2

 

100

 

   High TLI

78.7

 

76.4

 

Patients with stage II (n = 138)

 

0.464

 

0.070

   Low TLI

79.8

 

95.4

 

   High TLI

74.2

 

89.7

 

Patients with stage III (n = 76)

 

0.526

 

0.800

   Low TLI

65.7

 

76.3

 

   High TLI

63.2

 

73.4

 

Patients with node-negative disease (n = 114)

 

0.994

 

0.188

   Low TLI

83.5

 

92.6

 

   High TLI

86.1

 

88.6

 

Patients with node-positive disease (n = 154)

 

0.142

 

0.113

   Low TLI

72.6

 

86.4

 

   High TLI

61.2

 

73.6